Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus

Pediatric Diabetes

Volumn 9, Issue 5, 2008, Pages 472-479

  Skogsberg, Lars ^a   Fors, Hans ^b   Hanas, Ragnar ^c   Chaplin, J E ^d   Lindman, Elisabeth ^a   Skogsberg, Josefin ^e  

^a GÄVLE HOSPITAL   (Sweden)

^b Mammography Section   (Sweden)

^c UDDEVALLA HOSPITAL   (Sweden)

^d SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; ISOPHANE INSULIN;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD HEALTH CARE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES TREATMENT SATISFACTION QUESTIONNAIRE; DIABETIC KETOACIDOSIS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MORNING DOSAGE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADOLESCENT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; PATIENT SATISFACTION;

EID: 52649128311     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2008.00390.x     Document Type: Article

References (37)

1. Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: An approach to achieving normoglycaemia. Br Med J 1978: 1: 204-207.
2. Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979: 300: 573-578.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
4. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994: 125: 177-188.
5. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999: 22: 1779-1784.
6. Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP. Continuous subcutaneous insulin infusion therapy for children and adolescents: An option for routine diabetes care. Pediatrics 2001: 107: 351-356.
7. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: Meta-analysis of randomised controlled trials. BMJ 2002: 324: 705.
8. The Swedish National Paediatric Diabites Registry (S wediabkids). 2006 (available from www.ndr.nu).
9. Ahern JA, Boland EA, Doane R et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower hba1c levels across all age groups. Pediatr Diabetes 2002: 3: 10-15.
10. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003: 26: 1142-1146.
11. Hanas R, Adolfsson P. Insulin pumps in pediatric routine care improve long-term metabolic control without increasing the risk of hypoglycemia. Pediatr Diabetes 2006: 7: 25-31.
12. de Beaufort CE, Houtzagers CM, Bruining GJ et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: Two-year follow-up of a randomized, prospective trial. Diabet Med 1989: 6: 766-771.
13. Slijper FM, De Beaufort CE, Bruining GJ et al. Psychological impact of continuous subcutaneous insulin infusion pump therapy in non-selected newly diagnosed insulin dependent (type 1) diabetic children: Evaluation after two years of therapy. Diabete Metab 1990: 16: 273-277.
14. Pozzilli P, Crino A, Schiaffini R et al. A 2-year pilot trial of continuous subcutaneous insulin infusion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (imdiab 8). Diabetes Technol Ther 2003: 5: 965-974.
15. Ramchandani N, Ten S, Anhalt H et al. Insulin pump therapy from the time of diagnosis of type 1 diabetes. Diabetes Technol Ther 2006: 8: 663-670.
16. Weintrob N, Benzaquen H, Galatzer A et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: A randomized open crossover trial. Pediatrics 2003: 112: 559-564.
17. Mc Mahon SK, Airey FL, Marangou DA et al. Insulin pump therapy in children and adolescents: Improvements in key parameters of diabetes management including quality of life. Diabet Med 2005: 22: 92-96.
18. National Guidelines for Children with Diabetes in Sweden. Lund: Studentlitteratur, 1996.
19. Handbook of Psychology and Diabetes. Amsterdam: Harwood Academic Publishers, 1994.
20. Lindgren G, Strandell A, Cole T, Healy M, Tanner J. Swedish population reference standards for height, weight and body mass index attained at 6 to 16 years (girls) or 19 years (boys). Acta Paediatr 1995: 84: 1019-1028.
21. Hoelzel W, Weykamp C, Jeppsson JO et al. Ifcc reference system for measurement of hemoglobin a1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: A method-comparison study. Clin Chem 2004: 50: 166-174.
22. Bradle YC, Gamsu DS. Guidelines for encouraging psychological well-being: Report of a Working Group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. Diabet Med 1994: 11: 510-516.
23. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med 1990: 7: 445-451.
24. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with nph in patients with type 1 diabetes. Diabet Med 2001: 18: 619-625.
25. Dost A, Herbst A, Kintzel K et al. Shorter remission period in young versus older children with diabetes mellitus type 1. Exp Clin Endocrinol Diabetes 2007: 115: 33-37.
26. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004: 27: 1554-1558.
27. Wake M, Hesketh K, Cameron F. The child health questionnaire in children with diabetes: Cross-sectional survey of parent and adolescent-reported functional health status. Diabet Med 2000: 17: 700-707.
28. Bradley C, Speight J. Patient perceptions of diabetes and diabetes therapy: Assessing quality of life. Diabetes Metab Res Rev 2002: 18 (Suppl. 3): S64-S69.
29. Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002: 141: 490-495.
30. Madsbad S, Alberti KG, Binder C et al. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J 1979: 2: 1257-1259.
31. Dixon B, Peter Chase H, Burdick J et al. Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes 2005: 6: 150-154.
32. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. study group of insulin glargine in type 1 diabetes. Diabetes Care 2000: 23: 639-643.
33. Schober E, Schoenle E, Van Dyk J, Wernicke -Panten K. Comparative trial between insulin glargine and nph insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002: 15: 369-376.
34. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, nph insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000: 49: 2142-2148.
35. Feltbower RG, Campbell FM, Bodansky HJ, Stephenson CR, Mc Kinney PA. Insulin pump therapy in childhood diabetes-cost implications for primary care trusts. Diabet Med 2006: 23: 86-89.
36. Scuffham P, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 2003: 20: 586-593.
37. The Swedish Pharmaceutical Reimbursement System, Price List. 2007.